137 related articles for article (PubMed ID: 38639169)
1. Safety and efficacy of drug-eluting stents for patients at high risk of bleedings: A network meta-analysis.
Giacobbe F; Valente E; Morena A; Nebiolo M; Giannino G; De Filippo O; Bruno F; Isaevska E; Richiardi L; Iannaccone M; Zoccai GB; Burzotta F; D'Ascenzo F; Ferrari GM
Catheter Cardiovasc Interv; 2024 May; 103(6):843-855. PubMed ID: 38639169
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of drug eluting stents compared with bare metal stents in high bleeding risk patients undergoing percutaneous coronary interventions.
Neupane S; Khawaja O; Edla S; Singh H; Othman H; Bossone E; Yamasaki H; Rosman HS; Eggebrecht H; Mehta RH
Catheter Cardiovasc Interv; 2019 Jul; 94(1):98-104. PubMed ID: 30585391
[TBL] [Abstract][Full Text] [Related]
3. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
Kandzari DE; Kirtane AJ; Windecker S; Latib A; Kedhi E; Mehran R; Price MJ; Abizaid A; Simon DI; Worthley SG; Zaman A; Choi JW; Caputo R; Kanitkar M; McLaurin B; Potluri S; Smith T; Spriggs D; Tolleson T; Nazif T; Parke M; Lee LC; Lung TH; Stone GW;
Circ Cardiovasc Interv; 2020 Nov; 13(11):e009565. PubMed ID: 33167705
[TBL] [Abstract][Full Text] [Related]
4. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
[TBL] [Abstract][Full Text] [Related]
5. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
6. Drug-Eluting Versus Bare-Metal Stents in Older Patients: A Meta-Analysis of Randomized Controlled Trials.
Kheiri B; Osman M; Abdalla A; Haykal T; Chahine A; Gwinn M; Ahmed S; Hassan M; Bachuwa G; Bhatt DL
Cardiovasc Revasc Med; 2019 Sep; 20(9):744-751. PubMed ID: 30446398
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy: A Meta-analysis.
Shah R; Rao SV; Latham SB; Kandzari DE
JAMA Cardiol; 2018 Nov; 3(11):1050-1059. PubMed ID: 30383145
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
[TBL] [Abstract][Full Text] [Related]
9. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Polymer-Free Biolimus A9-Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy.
Carrié D; Menown I; Oldroyd K; Copt S; Talwar S; Maillard L; Morice MC; Teik LS; Lang I; Urban P
JACC Cardiovasc Interv; 2017 Aug; 10(16):1633-1642. PubMed ID: 28838473
[TBL] [Abstract][Full Text] [Related]
11. Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study.
Krucoff MW; Urban P; Tanguay JF; McAndrew T; Zhang Y; Rao SV; Morice MC; Price MJ; Cohen DJ; Abdel-Wahab M; Mehta SR; Faurie B; McLaurin B; Diaz C; Stoll HP; Pocock S; Leon MB
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008603. PubMed ID: 32279567
[TBL] [Abstract][Full Text] [Related]
12. Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial.
Lee JM; Park SD; Lim SY; Doh JH; Cho JM; Kim KS; Bae JW; Chung WY; Youn TJ
Trials; 2013 Nov; 14():398. PubMed ID: 24257456
[TBL] [Abstract][Full Text] [Related]
13. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
[TBL] [Abstract][Full Text] [Related]
14. Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up.
Sharma A; Agrawal S; Garg A; Vallakati A; Lavie CJ; Helft G
Catheter Cardiovasc Interv; 2017 Jul; 90(1):31-37. PubMed ID: 28557264
[TBL] [Abstract][Full Text] [Related]
15. Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antiplatelet Therapy.
Landi A; Wlodarczak A; Tölg R; Kelbæk H; Legutko J; Galli S; Godin M; Toth GG; Lhermusier T; Honton B; Dietrich PL; Stammen F; Ferdinande B; Silvain J; Capodanno D; Cayla G; Valgimigli M;
J Cardiovasc Transl Res; 2023 Oct; 16(5):1135-1143. PubMed ID: 37264295
[TBL] [Abstract][Full Text] [Related]
16. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
Kang SH; Chae IH; Park JJ; Lee HS; Kang DY; Hwang SS; Youn TJ; Kim HS
JACC Cardiovasc Interv; 2016 Jun; 9(12):1203-1212. PubMed ID: 27262860
[TBL] [Abstract][Full Text] [Related]
17. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
[TBL] [Abstract][Full Text] [Related]
18. Drug-Eluting Versus Bare Metal Stents in Saphenous Vein Graft Intervention: An Updated Comprehensive Meta-Analysis of Randomized Trials.
Bhogal S; Panchal HB; Bagai J; Banerjee S; Brilakis ES; Mukherjee D; Kumar G; Shanmugasundaram M; Paul TK
Cardiovasc Revasc Med; 2019 Sep; 20(9):758-767. PubMed ID: 30503811
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
[TBL] [Abstract][Full Text] [Related]
20. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.
Verdoia M; Kedhi E; Suryapranata H; Frati G; Biondi-Zoccai G; De Luca G
J Thromb Thrombolysis; 2020 Aug; 50(2):337-354. PubMed ID: 31919736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
